ARTICLE | Clinical News
AP301: Phase I started
April 18, 2011 7:00 AM UTC
Apeptico began a double-blind, placebo-controlled, dose-escalation, Austrian Phase I trial to evaluate a single dose of AP301 delivered via aerosol by nebulizer technology in up to 48 patients with lu...